Newsletter

Pipeline, markets, policy, and science. Once a week.

You’re in. Check your inbox to confirm.

More stories

In depth

Lilly's Retatrutide More Than Doubled Ozempic's Weight Loss

In the first Phase 3 head-to-head against another incretin, Lilly's retatrutide more than doubled Ozempic's weight loss in type 2 diabetes, at the cost of roughly triple the discontinuation rate on the top dose.

Read the story

Pipeline

See all